Introduction
The section provides an overview of Asacol Consumer Medicine Information in New Zealand. Asacol is a medication used to treat ulcerative colitis, a disease causing inflammation in the colon. The medication comes in tablet formulations containing mesalamine, an anti-inflammatory agent. It is essential to follow dosing guidelines and administration instructions carefully to ensure effective treatment. Recent reports indicate a supply constraint of 800 mg Asacol tablets. This article will delve deeper into the description, uses, side effects, administration, warnings, and regulatory status of Asacol tablets in New Zealand.
Overview of Asacol Consumer Medicine Information in New Zealand
Asacol, also known as mesalazine, is a medication used to treat ulcerative colitis, a condition characterized by inflammation in the colon. It is available in tablet formulations with different dosages, such as 400mg and 800mg tablets. The active ingredient in Asacol tablets is mesalamine, an anti-inflammatory agent. These tablets are designed to be taken orally and should be administered following specific guidelines to achieve optimal treatment outcomes. Recent reports have indicated a temporary supply constraint of the 800mg Asacol tablets in the New Zealand market; Understanding the consumer medicine information leaflet is crucial to comprehend the potential risks, benefits, dosage instructions, and possible side effects associated with Asacol tablets.
Asacol Description and Composition
Asacol is a medication containing mesalamine as the active ingredient, used in the treatment of ulcerative colitis, an inflammatory condition affecting the colon. The tablet formulation of Asacol is designed for oral administration, with each tablet containing a specific dosage of mesalamine. The composition of Asacol tablets includes an outer protective coat made of acrylic-based resins, Eudragit S, and Eudragit L. Understanding the composition and structure of Asacol tablets is essential for ensuring proper administration and effective treatment of ulcerative colitis.
Details on the Asacol Tablet Formulations and Active Ingredients
Asacol tablets come in different formulations, including enteric-coated tablets. The tablets contain mesalamine as the active ingredient, which is an anti-inflammatory agent used to treat ulcerative colitis. The enteric-coated tablets are designed to release mesalamine in the colon to target the inflammation effectively. Each Asacol HD delayed-release tablet contains 800 mg of mesalamine and is coated with a combination of acrylic-based resins, Eudragit S, and Eudragit L to protect the active ingredient.
Asacol, containing the active ingredient mesalazine, is utilized as an anti-inflammatory agent to manage and prevent episodes of ulcerative colitis. Ulcerative colitis, a condition affecting the large bowel or rectum, involves inflammation of the bowel lining. Mesalazine, present in Asacol tablets, aids in alleviating inflammation and reducing the likelihood of recurrent symptoms associated with ulcerative colitis. Understanding how Asacol works and its purpose in treating inflammatory bowel diseases like ulcerative colitis is crucial for patients prescribed this medication.
Explanation of How Asacol is Utilized to Treat Ulcerative Colitis
Asacol, also known as mesalazine, is an anti-inflammatory agent used to manage and prevent episodes of ulcerative colitis, a condition causing inflammation in the colon. Mesalazine, the active ingredient in Asacol, works by reducing inflammation in the bowel lining, helping alleviate symptoms associated with ulcerative colitis. Understanding how Asacol targets inflammation and its role in treating ulcerative colitis is essential for patients undergoing this treatment.
Possible Side Effects
When using Asacol, patients may experience common side effects such as burping, constipation, nausea, vomiting, stomach pain, diarrhea, and gas. Along with these, abnormal liver function tests have also been reported. For more severe side effects or if any other symptoms occur, it is advised to consult a healthcare provider promptly. Reporting any side effects to the FDA is essential to monitor and ensure the safety of the medication.
Uses of Asacol
Asacol, with the active ingredient mesalazine, is utilized as an anti-inflammatory agent to manage and prevent further episodes of ulcerative colitis. Ulcerative colitis affects the large bowel or rectum, leading to inflammation in the bowel lining. Mesalazine in Asacol helps alleviate inflammation in the colon, reducing symptoms associated with ulcerative colitis. Understanding the use of Asacol in treating inflammatory bowel conditions is essential for effective management.
Supply Constraints
Chiesi, the supplier of Asacol, has reported a supply constraint affecting the 800 mg Asacol tablets from late February until July 2024. The supply issue pertains to the 800 mg Asacol tabs, causing a temporary shortage in the market. This constraint may impact the availability of the medication for patients requiring this specific dosage. It is advisable for healthcare providers and patients to stay informed about the supply constraint and explore alternative treatment options if necessary.
Information on the Reported Supply Constraint of 800 mg Asacol Tabs
Chiesi, the supplier of Asacol, has communicated a supply constraint affecting the availability of 800 mg Asacol tablets from late February to July 2024. The temporary shortage of the 800 mg Asacol tabs could impact patients requiring this specific dosage for treating conditions such as ulcerative colitis. Patients and healthcare providers are advised to be aware of this supply constraint and consider alternative treatment options if necessary.
Administration and Dosage
Asacol tablets are designed for oral administration and are available as enteric-coated tablets. The standard dosage of Asacol tablets includes 400 mg and 800 mg formulations. Patients should follow the administration instructions provided in the Consumer Medicine Information to ensure proper intake and absorption. Understanding the correct dosage and administration guidelines for Asacol tablets is essential to maximize the effectiveness of the medication in treating conditions such as ulcerative colitis.
Guidelines on How to Take Asacol Orally and Dosage Information
Asacol tablets are intended for oral administration and are available as enteric-coated tablets in varying dosages, including 400 mg and 800 mg; Each tablet should be taken orally as directed, typically with a glass of water. It is essential to adhere to the prescribed dosage and administration schedule provided by healthcare professionals to ensure the optimal effectiveness of Asacol in managing conditions such as ulcerative colitis.
Warnings and Contraindications
Asacol, containing mesalazine as the active ingredient, is contraindicated in patients with severe liver or kidney problems. It is important for individuals with these conditions to avoid taking Asacol. Specific precautions include not substituting 800 mg Asacol tablets for other oral mesalamine products and evaluating renal function before starting Asacol. Additionally, the medication should be taken on an empty stomach as directed by healthcare providers to ensure optimal efficacy and safety.
Important Information Regarding When Not to Take Asacol
It is crucial not to take Asacol if you have severe liver or kidney problems. The medication is contraindicated in individuals with these conditions due to the potential risks associated. Patients with severe liver or kidney issues should avoid using Asacol. Additionally, it is important to follow medical advice and recommendations regarding the use of Asacol to ensure safety and efficacy.
Regulatory Status
Asacol, an enteric-coated tablet containing mesalazine as the active ingredient, has been approved and registered in New Zealand by Chiesi New Zealand Limited. The tablets are classified for specific medical use, aiming to treat conditions such as ulcerative colitis. Regulatory approval was granted in 1994٫ ensuring compliance with safety and efficacy standards. Understanding the regulatory status of Asacol tablets can provide insights into their availability and permitted uses within the country.
Details on the Listing and Funding of Asacol Tablets in New Zealand
Asacol tablets, including the 400 mg and 800 mg formulations٫ are approved and listed in New Zealand by Chiesi New Zealand Limited. These tablets contain mesalazine as the active ingredient and are classified for the treatment of conditions such as ulcerative colitis. The registration for Asacol was granted on February 24٫ 1994٫ making it available for use in the country. The tablets are funded and subsidized٫ ensuring accessibility for patients requiring this medication.
Leave a Reply